These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 30185816)

  • 1. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.
    Hall S; Janelidze S; Surova Y; Widner H; Zetterberg H; Hansson O
    Sci Rep; 2018 Sep; 8(1):13276. PubMed ID: 30185816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
    Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
    Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
    Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L
    JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF biomarkers and clinical progression of Parkinson disease.
    Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
    Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
    J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
    Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
    J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.